C4 Therapeutics, Inc.

Report azionario NasdaqGS:CCCC

Capitalizzazione di mercato: US$342.7m

C4 Therapeutics Gestione

Criteri Gestione verificati 4/4

C4 Therapeutics Il CEO è Andrew Hirsch, nominato in Sep2020, e ha un mandato di 5.67 anni. la retribuzione annua totale è $ 2.94M, composta da 23.6% di stipendio e 76.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.12% delle azioni della società, per un valore di $ 420.52K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.3 anni e 7.8 anni.

Informazioni chiave

Andrew Hirsch

Amministratore delegato

US$2.9m

Compenso totale

Percentuale dello stipendio del CEO23.63%
Mandato del CEO5.7yrs
Proprietà del CEO0.1%
Durata media del management5.3yrs
Durata media del Consiglio di amministrazione7.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Articolo di analisi • May 15

C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) defied analyst predictions to release its quarterly results, which were ahead of...
Seeking Alpha • Mar 10

C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact

Summary C4 Therapeutics delivered strong 4Q25 results, with revenue up 111.5% YoY and operating expenses tightly controlled. CCCC's lead asset, cemsidomide, advanced into a Phase 2 registrational trial for relapsed/refractory multiple myeloma, targeting a large, growing TAM. Cash position strengthened to $297.1M, extending operational runway through 2028 and supporting continued pipeline investment. Valuation remains highly discounted (EV/sales 1.66x), but future success hinges on cemsidomide trial outcomes and regulatory milestones. Read the full article on Seeking Alpha
Articolo di analisi • Dec 17

Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price

You may think that with a price-to-sales (or "P/S") ratio of 7.3x C4 Therapeutics, Inc. ( NASDAQ:CCCC ) is a stock...
Articolo di analisi • Sep 05

C4 Therapeutics, Inc. (NASDAQ:CCCC) Held Back By Insufficient Growth Even After Shares Climb 33%

Despite an already strong run, C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares have been powering on, with a gain of 33...
Articolo di analisi • Jul 11

C4 Therapeutics, Inc. (NASDAQ:CCCC) Surges 27% Yet Its Low P/S Is No Reason For Excitement

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares have continued their recent momentum with a 27% gain in the last month...
Articolo di analisi • Jun 20

We Think C4 Therapeutics (NASDAQ:CCCC) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Articolo di analisi • Apr 18

Investors Don't See Light At End Of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Tunnel And Push Stock Down 40%

Unfortunately for some shareholders, the C4 Therapeutics, Inc. ( NASDAQ:CCCC ) share price has dived 40% in the last...
Seeking Alpha • Mar 10

C4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk Here

Summary C4 Therapeutics' pipeline, including cemsidomide and CFT1946, shows early promise but faces significant safety concerns and long timelines for definitive data readouts. Financially, CCCC has sufficient cash to fund operations into 2027, reducing immediate dilution risk, but high cash burn remains a concern. Market valuation has dropped significantly, aligning more closely with their early-stage clinical status, reducing overvaluation risk. Despite potential in protein degraders, the current "Hold" sentiment is maintained due to early-stage data and lack of near-term catalysts. Read the full article on Seeking Alpha
Articolo di analisi • Mar 04

C4 Therapeutics, Inc. (NASDAQ:CCCC) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough

To the annoyance of some shareholders, C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares are down a considerable 31% in the...
Articolo di analisi • Nov 15

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders won't be pleased to see that the share price has had a very rough...
Seeking Alpha • Nov 06

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout

Summary C4 Therapeutics has a promising pipeline, including cemsidomide for blood cancer and CFT1946 for solid tumors, but definitive data is still far off. Financially stable with $59.6M in cash and $196M in marketable securities, CCCC has a cash runway of 11-12 quarters, funding operations through 2025. Strengths include controlled costs and no imminent dilution risk, but the long wait for significant data readouts poses a risk for investors. Maintain a "Hold" rating; worth watching for patient, risk-tolerant investors, but not advisable to jump in headfirst just yet. Read the full article on Seeking Alpha
Articolo di analisi • Oct 02

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, C4 Therapeutics...
Articolo di analisi • Aug 09

Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...
Articolo di analisi • Aug 03

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Those holding C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares would be relieved that the share price has rebounded 41% in...
Articolo di analisi • May 12

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Mar 01

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Summary C4 Therapeutics is developing targeted protein degraders for the treatment of various diseases, including cancer. The company's TORPEDO platform allows for the design of molecules that can break down disease-causing proteins. C4 Therapeutics has a partnership with Merck and is currently in Phase 1 clinical trials for its drug candidates. The company's current valuation appears high compared to sector peers, leading to a "hold" rating. Read the full article on Seeking Alpha
Articolo di analisi • Feb 29

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Shareholders in C4 Therapeutics, Inc. ( NASDAQ:CCCC ) may be thrilled to learn that the analysts have just delivered a...
Articolo di analisi • Feb 24

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

It's been a pretty great week for C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders, with its shares surging 13% to...
Articolo di analisi • Nov 03

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Andrew Hirsch rispetto agli utili di C4 Therapeutics?
DataCompenso totaleStipendioUtili della società
Mar 31 2026n/an/a

-US$104m

Dec 31 2025US$3mUS$695k

-US$105m

Sep 30 2025n/an/a

-US$119m

Jun 30 2025n/an/a

-US$112m

Mar 31 2025n/an/a

-US$103m

Dec 31 2024US$5mUS$665k

-US$105m

Sep 30 2024n/an/a

-US$105m

Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$126m

Dec 31 2023US$4mUS$639k

-US$132m

Sep 30 2023n/an/a

-US$135m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$131m

Dec 31 2022US$3mUS$614k

-US$128m

Sep 30 2022n/an/a

-US$107m

Jun 30 2022n/an/a

-US$99m

Mar 31 2022n/an/a

-US$95m

Dec 31 2021US$952kUS$580k

-US$84m

Sep 30 2021n/an/a

-US$80m

Jun 30 2021n/an/a

-US$82m

Mar 31 2021n/an/a

-US$73m

Dec 31 2020US$21mUS$168k

-US$66m

Compensazione vs Mercato: La retribuzione totale di Andrew ($USD 2.94M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 2.72M ).

Compensazione vs guadagni: La retribuzione di Andrew è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Andrew Hirsch (54 yo)

5.7yrs
Mandato
US$2,940,975
Compensazione

Mr. Andrew J. Hirsch, M.B.A., is Independent Director of Akamis Bio Limited from August 2025. He is the President of C4 Therapeutics, Inc since September 14, 2020 and has been its Chief Executive Officer s...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Andrew Hirsch
CEO, President & Director5.7yrsUS$2.94m0.12%
$ 420.5k
Kenneth Anderson
Co-Founderno dataUS$85.50k0.32%
$ 1.1m
Kendra Adams
Chief Financial Officer and Head of Corporate Affairs & Treasurer2.7yrsUS$1.48m0.041%
$ 140.5k
Leonard M. Reyno
Chief Medical Officer2.8yrsUS$1.64m0.023%
$ 79.2k
Nathanael Gray
Co-Founder & Member of Scientific Advisory Boardno dataNessun datoNessun dato
Mark Mossler
Chief Accounting Officer2.7yrsNessun dato0.0053%
$ 18.0k
Paige Mahaney
Chief Scientific Officer1.6yrsNessun dato0.016%
$ 56.5k
Courtney Solberg
Senior Manager of Investor Relationsno dataNessun datoNessun dato
Kelly Schick
Chief People Officer5.3yrsNessun dato0.035%
$ 120.9k
Isabel Chiu
Senior Vice President of Strategic Alliances & Business Development10.2yrsNessun datoNessun dato
Christopher Nasveschuk
Senior Vice President of Chemistry5.3yrsNessun datoNessun dato
Roy Pollock
Senior Vice President of Biological Sciences7.3yrsNessun datoNessun dato
5.3yrs
Durata media
54yo
Età media

Gestione esperta: Il team dirigenziale di CCCC è esperto e expertise (durata media dell'incarico 5.3 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Andrew Hirsch
CEO, President & Director5.6yrsUS$2.94m0.12%
$ 420.5k
Kenneth Anderson
Co-Founder10.4yrsUS$85.50k0.32%
$ 1.1m
Nathanael Gray
Co-Founder & Member of Scientific Advisory Board9.5yrsNessun datoNessun dato
Christopher Bowden
Member of Clinical Advisory Boardno dataNessun datoNessun dato
Steven Hoerter
Independent Director1.5yrsUS$90.31kNessun dato
Christopher Kirk
Member of Scientific Advisory Board9.5yrsNessun datoNessun dato
Ross Levine
Member of Scientific Advisory Board8.8yrsNessun datoNessun dato
Ronald H. Cooper
Independent Chairman1.9yrsUS$119.25k0%
$ 0
Ryan Corcoran
Member of Scientific Advisory Board6.7yrsNessun datoNessun dato
Scott Armstrong
Member of Scientific Advisory Board8.8yrsNessun datoNessun dato
Utpal Koppikar
Independent Director4.2yrsUS$100.50k0.0051%
$ 17.6k
Beni Wolf
Member of Clinical Advisory Boardno dataNessun datoNessun dato
7.8yrs
Durata media
54yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CCCC sono considerati esperti (durata media dell'incarico 7.8 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/20 03:43
Prezzo dell'azione a fine giornata2026/05/20 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

C4 Therapeutics, Inc. è coperta da 15 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Etzer DaroutBarclays
Chi Meng FongBofA Global Research
Leah Rush CannBrookline Capital Markets